Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...
Hosted on MSN22h
Donald Trump and RFK Jr want to ‘Make America Healthy Again’. Where does that leave Europe?“The European Medicines Agency might supplant the FDA as the gold standard if the FDA goes off track and is politically ...
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ... Read ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...
Johnson & Johnson seeks US & EU approvals for Darzalex Faspro/Darzalex as subcutaneous monotherapy for high-risk smoldering multiple myeloma: Raritan, New Jersey Monday, November ...
Dallas Morning News on MSN3d
FDA adds new warning to weight loss drugs including WegovyThe FDA is warning that patients taking GLP-1s may be at a higher risk of inhaling fluid into their lungs while under ...
China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western ...
Interim analysis for Study 1 of Essential3 Phase 3 program for ulixacaltamide in essential tremor (ET) confirmed for Q1 2025; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback